ClinicalTrials.gg
Not yet recruitingNCT05060731FIERCEUpdated Mar 30, 2025

Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding

A Phase 4 interventional study of Oral iron supplementation and Intravenous iron supplementation in GastroIntestinal Bleeding and Anemia, sponsored by University of Pecs. Not yet recruiting at 1 site in Hungary. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by University of Pecs · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Anemia is a frequent complication of gastrointestinal bleeding, affecting 61% of the patients. Currently, anemia caused by gastrointestinal bleeding can be treated with iron supplementation. However, the dose and route of the administration are still a question. The FIERCE clinical trial aims to compare the effect of intravenous iron supplementation and oral iron replacement on mortality, unplanned emergency visits, and hospital readmissions in multimorbid patients with acute nonvariceal gastrointestinal bleeding.

Read the detailed description

In gastrointestinal bleeding (GIB) iron deficiency anemia (IDA) is a common complication, affecting more than 60% of the patients. There are two pillars of the treatment of acute GIB. First, the bleeding point needs identification and endoscopic treatment. Second, the resulting hypovolemia and anemia require fluid resuscitation, transfusion, and replacement of the lost iron. There are two simple ways to manage IDA after acute GIB. Patients either have intravenous (IV) iron infusions one to six times as part of their hospital treatment or receive three months of oral iron supplementation. There is a gap in current guidelines on which approach clinicians should choose.

Here the investigators plan a multicentric, two-arm, randomized controlled trial, to compare the efficacy of oral and intravenous iron supplementation in multimorbid patients with acute nonvariceal gastrointestinal bleeding. Patients will be randomly allocated in a 1:1 ratio to two groups. Group A will receive one dose of 1000 mg of IV ferric carboxymaltose on the day of randomization, while iron supplementation for group B will be performed with one ferrous sulfate tablet every day (ca. 200-300 mg) for three months. The primary outcome will be the composite outcome of all-cause mortality, unplanned emergency visit, and unplanned hospital readmission within six months after enrollment.

In the first phase, the investigators plan to recruit 15 patients on each arm to assess the proportion of the primary outcome in the two groups. In the second phase, a sample size calculation for the primary outcome will be performed based on the results of the first phase.

02

Conditions studied

  • GastroIntestinal Bleeding
  • Anemia

Keywords

  • non-variceal upper gastrointersinal bleeding
  • iron supplementation
  • intravenous iron
03

In context

Gastrointestinal Hemorrhage

338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.

This study's planned enrollment of 570 is above the median of 98 across 210 interventional studies indexed under Gastrointestinal Hemorrhage.

Browse Gastrointestinal Hemorrhage studies →

Lead sponsor

University of Pecs is the lead sponsor of 107 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age ≥ 65 years;
  2. endoscopically proven acute nonvariceal GIB source;
  3. 48 hours after the endoscopic diagnosis and/or treatment;
  4. hemodynamically stable;
  5. the discharge of the patient is planned;
  6. level \<10 g/dl on the day of randomisation;
  7. 24 hours after the last transfusion and no need for further transfusion;
  8. signed .

Exclusion criteria

Exclusion Criteria:

  1. known to iron products (mild side effects excluded);
  2. previous diagnosis of iron overload [e.g., transferrin receptor saturation (TSAT) >50%, ferritin> 160 for women ng/ml, ferritin >270 ng/ml for men) or disorders of iron utilisation;
  3. pregnancy or breast feeding;
  4. diagnosis of iron malabsorption (at discretion of the attending clinician; e.g., severe inflammatory bowel disease, active celiac disease);
  5. chronic end stage diseases (chronic heart failure- Classification class 4, chronic kidney disease ( \<30 mL/min/1.73 m2) with or without dialysis, liver cirrhosis with C score, chronic kidney disease with dialysis, stage 4, chronic inflammatory disease, , AIDS);
  6. active malignancies;
  7. liver cirrhosis with known varices at high risk of bleeding - endoscopic features of high risk of variceal bleeding or liver stiffness measured by transient elastography >20 kiloPascal and count \<150 × 10\^9 cells/L;
  8. gastrointestinal tract malignancies with high risk of gastrointestinal bleeding;
  9. high risk of poor compliance or no fixed abode;
  10. myelo- or lymphoproliferative diseases;
  11. anemia not attributable to iron deficiency (sideroblastic anaemia, aplastic anaemia, haemolytic anaemia, thalassaemia, B12 vitamin or folic acid deficiency or combination of these with IDA);
  12. primary coagulation disorders (e.g. Glanzmann thrombasthenia, Von Willebrand disease, Haemophylia A, Haemophylia B);
  13. the patient will be transferred to another institute after discharge (e.g. hospital, senior care center);
  14. (ECOG) Performance Status >2.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
570 participants (estimated)

Study arms

  • Active comparator
    Oral iron supplementation

    Patients randomized to receive oral ferrous sulfate, ca. 200-300 mg every day for 3 months.

    Drug: Oral iron supplementation

  • Active comparator
    Intravenous iron supplementation

    Patients randomized to receive one dose of 1000 mg intravenous ferric carboxymaltose.

    Drug: Intravenous iron supplementation

Interventions

  • DrugOral iron supplementation

    Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.

  • DrugIntravenous iron supplementation

    One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.

06

What researchers measure

Primary outcomes

  1. Composite outcome

    The composite endpoint includes all-cause mortality, unplanned emergency visit (general practitioner or emergency outpatient clinic), and unplanned hospital admission for any reason. The investigators will calculate the proportion of the outcome in each arm.

    Time frame: 3 months

Secondary outcomes

  1. All-cause mortality

    Death from any cause. The proportion of the outcome will be calculated in each arm and compared between the arms. The investigators will compare subgroups of patients based on the cause of mortality.

    Time frame: 1, and 3 months

  2. Unplanned emergency visits

    Emergency visit from any cause. The proportion of the outcome will be calculated in each arm and compared between the arms. The investigators will compare subgroups of patients based on the cause of unplanned emergency visits.

    Time frame: 1, and 3 months

  3. Unplanned hospital admission

    Hospital admission from any cause. The proportion of the outcome will be calculated in each arm and compared between the arms. The investigators will compare subgroups of patients based on the cause of unplanned admission.

    Time frame: 1, and 3 months

  4. Quality of life using the 36-Item Short-Form Health Survey

    Changes in quality of life measured with the 36-Item Short-Form Health Survey (SF-36) questionnaire compared to baseline.

    Time frame: 1, and 3 months +/- 7 days

  5. Quality of life using the EuroQol five-dimensions - 5 levels questionnare

    Changes in quality of life measured with the EuroQol five-dimensions - 5 levels (EQ-5D-5L) questionnaire compared to baseline.

    Time frame: 1, and 3 months +/- 7 days

  6. Gait speed

    Changes in gait speed compared to baseline. Gait speed will be evaluated on a 4-meter flat walking path.

    Time frame: 1, and 3 months +/- 7 days

  7. Six-Minute Walk Test (6MWT)

    Changes in Six-Minute Walk Test (6MWT) compared to baseline.

    Time frame: 1, and 3 months +/- 7 days

  8. Handgrip strength

    Changes in handgrip strength compared to baseline.

    Time frame: 1, and 3 months +/- 7 days

  9. Normalization of the haemoglobin level

    The percentage of participants with Hb levels of ≥12 g/dL in women and ≥13 g/d, compared to baseline.

    Time frame: 1, and 3 months +/- 7 days

  10. Change in Hb level

    Absolute change from baseline to follow-up in Hb level.

    Time frame: 1, and 3 months +/- 7 days

  11. Change in haematocrit

    Absolute change from baseline to follow-up in haematocrit.

    Time frame: 1, and 3 months +/- 7 days

  12. Change in serum iron level

    Absolute change from baseline to follow-up in serum iron level.

    Time frame: 1, and 3 months +/- 7 days

  13. Change in serum transferrin level

    Absolute change from baseline to follow-up in serum transferrin level.

    Time frame: 1, and 3 months +/- 7 days

  14. Change in transferrin saturation

    Absolute change from baseline to follow-up in transferrin saturation.

    Time frame: 1, and 3 months +/- 7 days

  15. Change in soluble transferrin receptor concentration

    Absolute change from baseline to follow-up in soluble transferrin receptor (sTfR) concentration.

    Time frame: 1, and 3 months +/- 7 days

  16. Change in ferritin level

    Absolute change from baseline to follow-up in ferritin level.

    Time frame: 1, and 3 months +/- 7 days

  17. Change in the number of reticulocytes

    Absolute change from baseline to follow-up in the number of reticulocytes.

    Time frame: 1, and 3 months +/- 7 days

  18. Change in the number of erythrocytes

    Absolute change from baseline to follow-up in the number of erythrocytes.

    Time frame: 1, and 3 months +/- 7 days

  19. Change in the total iron-binding capacity

    Absolute change from baseline to follow-up in the total iron-binding capacity (TIBC).

    Time frame: 1, and 3 months +/- 7 days

  20. Change in erythropoietin level

    Absolute change from baseline to follow-up in erythropoietin level.

    Time frame: 1, and 3 months +/- 7 days

  21. Change in C-reactive protein level

    Absolute change from baseline to follow-up in the C-reactive protein level.

    Time frame: 1, and 3 months +/- 7 days

  22. Change in hepcidin level

    Absolute change from baseline to follow-up in hepcidin level.

    Time frame: 1, and 3 months +/- 7 days

  23. Change in phosphate level

    Absolute change from baseline to follow-up in phosphate level.

    Time frame: 1, and 3 months +/- 7 days

  24. Discontinuation of the treatment due to adverse events

    The percentage of discontinuation in the two arms.

    Time frame: 1, and 3 months +/- 7 days

  25. Cost-effectiveness

    The incremental cost-effectiveness ratio (ICER): incremental costs divided by incremental effectiveness .

    Time frame: 1, and 3 months +/- 7 days

07

Study locations

1 site
08

References and documents

Publications

  • McNutt MK, Bradford M, Drazen JM, Hanson B, Howard B, Jamieson KH, Kiermer V, Marcus E, Pope BK, Schekman R, Swaminathan S, Stang PJ, Verma IM. Transparency in authors' contributions and responsibilities to promote integrity in scientific publication. Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2557-2560. doi: 10.1073/pnas.1715374115. Epub 2018 Feb 27. PubMed 29487213 ↗
  • McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr. 2009 Apr;12(4):444-54. doi: 10.1017/S1368980008002401. Epub 2008 May 23. PubMed 18498676 ↗
  • Ferrer-Barcelo L, Sanchis Artero L, Sempere Garcia-Arguelles J, Canelles Gamir P, P Gisbert J, Ferrer-Arranz LM, Monzo Gallego A, Plana Campos L, Huguet Malaves JM, Lujan Sanchis M, Ruiz Sanchez L, Barcelo Cerda S, Medina Chulia E. Randomised clinical trial: intravenous vs oral iron for the treatment of anaemia after acute gastrointestinal bleeding. Aliment Pharmacol Ther. 2019 Aug;50(3):258-268. doi: 10.1111/apt.15327. Epub 2019 Jun 14. PubMed 31197861 ↗
  • Bager P, Dahlerup JF. Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage--a placebo-controlled study. Aliment Pharmacol Ther. 2014 Jan;39(2):176-87. doi: 10.1111/apt.12556. Epub 2013 Nov 19. PubMed 24251969 ↗
  • Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015 Feb 20;10(2):e0117383. doi: 10.1371/journal.pone.0117383. eCollection 2015. PubMed 25700159 ↗
  • Sultan P, Bampoe S, Shah R, Guo N, Estes J, Stave C, Goodnough LT, Halpern S, Butwick AJ. Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019 Jul;221(1):19-29.e3. doi: 10.1016/j.ajog.2018.12.016. Epub 2018 Dec 19. PubMed 30578747 ↗
  • Cotter J, Baldaia C, Ferreira M, Macedo G, Pedroto I. Diagnosis and treatment of iron-deficiency anemia in gastrointestinal bleeding: A systematic review. World J Gastroenterol. 2020 Dec 7;26(45):7242-7257. doi: 10.3748/wjg.v26.i45.7242. PubMed 33362380 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Dec 2027, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2021
First posted
Sep 29, 2021
StartEst.
Sep 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Feb 1, 2028
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05060731
Lead sponsor
University of Pecs
Responsible party
dr Erőss Bálint (Principal Investigator, Director of the Centre for Translational Medicine at University of Pécs, University of Pecs) — Principal investigator
First posted
Sep 29, 2021
Start date
Sep 1, 2025 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Mar 30, 2025

Study contacts

Bálint Erőss, MD, PhD
Contact
eross.balint@pte.hu
+3630/887-4028
Péter Hegyi, MD, PhD, DSc, MAE
Contact
p.hegyi@tm-centre.org
+3670/375-1031

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion